Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Cellulose-Based Scaffolds with Prolonged Dexamethasone Release for Bone Tissue Engineering

Liesienė J., Baniukaitiene O., Minseviciene I.

Laboratory Study on Chronic Inflammation, published in Molecules (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Molecules (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40649278
PMCID
PMC12251136
DOI
10.3390/molecules30132760
Citations
1

Abstract (original English)

The implantation of bone substitutes is frequently accompanied by inflammation. To reduce the inflammatory response and enhance cell adhesion, proliferation, and differentiation, scaffolds are often loaded with anti-inflammatory drugs. In this study, cellulose and cellulose/hydroxyapatite (1:1 by weight) scaffolds were developed. Structural analysis using SEM and micro-computed tomography revealed that the morphology of the scaffolds met the requirements for bone tissue engineering. The scaffolds were initially loaded with dexamethasone sodium phosphate; however, the drug was released very rapidly. To prolong its release, cationic groups were introduced into the cellulose macromolecules by amination with 2-chloro-N,N-diethylethylamine hydrochloride in an alkaline medium. Dexamethasone sodium phosphate was then immobilised on aminated cellulose and aminated cellulose/HAp scaffolds at concentrations of 157 mg/g and 87 mg/g, respectively. Due to ionic interactions between the cationic groups in the scaffolds and the anionic groups of the drug molecules, drug release was effectively prolonged. After 24 h, only about 6-7% of the drug had been released, with complete release occurring after 170 h. The cationic groups in the scaffold framework facilitated the adsorption and sustained release of dexamethasone sodium phosphate.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Bone and BonesDurapatiteDexamethasoneCelluloseAnti-Inflammatory AgentsDelayed-Action PreparationsTissue EngineeringTissue ScaffoldsDrug Liberation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research